Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism

Abstract EN

Aim.

To investigate the correlation of Fuzheng-Huayu tablet (FZHY) efficacy on chronic hepatitis B caused cirrhosis (HBC) and single nucleotide polymorphisms (SNPs) of CYP1A2.

Methods.

After 111 cases of HBC with 69 excess, 21 deficiency-excess, and 21 deficiency ZHENGs (ZHENG, also called traditional Chinese medicine syndrome) were treated by FZHY for 6 months, clinical symptoms, Child-Pugh score, and ZHENG score were observed.

Three of the SNPs in CYP1A2 gene were detected and analyzed using SNaPshot assay.

Results.

In ZHENG efficacy between effective and invalid groups, there was significant difference (P<0.001).

The ZHENG deficiency was significantly correlated with FZHY efficacy (P<0.05).

AA genotype of CYP1A2-G2964A was significantly different with GG genotype (P<0.05) between CYP1A2 Genotypes and FZHY efficacy on ZHENG.

More importantly, GA plus AA genotype of CYP1A2-G2964A was significantly different with deficiency ZHENG (P<0.05) between CYP1A2 genotypes and FZHY efficacy on ZHENG.

Conclusion.

FZHY improved ZHENG score of HBC, and these efficacies may relate to CYP1A2-G2964A sites.

It was suggested that CYP1A2-G2964A locus is probably a risk factor for ZHENG-based FZHY efficacy in HBC.